PTMA gene is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Enantiomers of a chiral drug often interact in an enantioselective way in a chiral environment. This may be offered by different biotic substances (viz. proteins, nucleic acids, phospholipids and oligosaccharides). They are made up of chiral building blocks that are put together in space in handed conformations. These biological targets function as receptors for the drug enantiomers. So, at the binding sites of these receptors, enantiomers will be seen as different chemical species. The three point attachment model (Easson & Stedman model) can be used to see how chiral discrimination works. Figure depicts how the enantiomers of a drug interact with receptors in a way that depends on the drug's shape. This model was made for chiral drugs with a single stereogenic center. It says that there are three binding sites in the receptor (B', C' and D') that match the drug's pharmacophoric groups (B, C, D). A three-point fit (good fit) is possible for the eutomer at BB', CC' and DD'(Fig. A). Even though the distomer is the wrong enantiomer, it can fit either a one-point interaction (bad fit), or a two-point attachment (CC' and DD') with the same receptor site as shown in (Fig. B). Eutomer is the version that works the way you want it to, and distomer is the version that doesn't work or works in a way you don't want it to. Most of the time, the mirror-image versions have different binding affinities. In the eutomer, the ligands or moiety around a stereogenic element have more binding energy than in the distomer.
radiality [characteristic of most stems] and dorsiventrality [characteristic of leaves] are but extremes of a continuous spectrum. In fact, it is simply the timing of the KNOX gene expression!." Eckardt and Baum (2010) concluded that "it is now generally accepted that compound leaves express both leaf and shoot properties." Process morphology describes and analyses the dynamic continuum of plant form. According to this approach, structures do not have process(es), they are process(es). Thus, the structure/process dichotomy is overcome by "an enlargement of our concept of 'structure' so as to include and recognise that in the living organism it is not merely a question of spatial structure with an 'activity' as something over or against it, but that the concrete organism is a spatio-temporal structure and that this spatio-temporal structure is the activity itself". For Jeune, Barabé and Lacroix, classical morphology (that is, mainstream morphology, based on a qualitative homology concept implying mutually exclusive categories) and continuum morphology are sub-classes of the more encompassing process morphology (dynamic morphology). Classical morphology, continuum morphology, and process morphology are highly relevant to plant evolution, especially the field of plant evolutionary biology (plant evo-devo) that tries to integrate plant morphology and plant molecular genetics.
=== Toxicity evaluation === BPF is under preliminary research to determine its potential toxicity, which may include airway irritation if BPF dust is inhaled, and an allergic reaction if it is in contact with the skin.
== MP for Glasgow Hillhead and Kelvin (1987–2005) == At the 1987 general election, Galloway was elected as the MP for Glasgow Hillhead gaining the seat for Labour from the SDP defeating Roy Jenkins with a majority of 3,251 votes. Although known for his left-wing political views, Galloway was never a member of the Campaign Group.
Phase two of the plan, known as "Opportunity", began in July 2019 and called for the creation of programs and initiatives to prevent youths predisposed to crime from engaging in criminal activity. The programs and initiatives included creating scholarships, building schools and sports centers, and improving healthcare. Bukele established the Social Fabric Revitalization Unit to implement the phase. Phase three, known as "Modernization", began in August 2019 and called for the improvement of equipment used by the country's security forces; it included issuing new weapons, gear, helicopters, and drones to the security forces. Phase four, known as "Incursion", began in July 2021 when the security forces began patrolling areas with a high gang presence that were considered difficult to access. Phase five, known as "extraction", began in November 2022. Security forces were ordered to "surround large cities and extract the terrorists [gang members] who [were] hiding within the communities, without giving them the slightest possibility of escape". Phase six, known as "integration", began in September 2023, when Bukele established the National Integration Directory to combat poverty and unemployment. Details about phase seven, which has not yet been implemented, are not publicly known. El Salvador's homicide rate has decreased every year of Bukele's presidency, a downward trend that began in 2016.
Sources: en.wikipedia.org
=== Rosenberg === Dr. Rosenberg (voiced by Jon St. John) is a scientist and a survivor of the Black Mesa incident. He first appears in Half-Life: Decay. When Gina Cross and Colette Green first arrive at the test chamber's control room and are receiving instructions from Dr. Keller, Rosenberg interrupts and voices his concern to Keller over having the anti-mass spectrometer run above 90% capacity, which is past the safety buffer zone for the equipment. Dr. Keller, however, dismisses his concern and states that the administrator's orders for this were clear. He tells Rosenberg that he can either stay and watch the experiment or return to his labs by the train yards. Rosenberg remains, and shortly thereafter the Resonance Cascade occurs. Immediately after the disaster, Rosenberg converses with Dr. Keller and makes it clear that he believes their greatest responsibility should be the safety of the people at Black Mesa. Although Keller thinks that they should attempt to reset the displacement fields first, he eventually agrees with Rosenberg, and they come up with a plan to contact the military, so that they can help and evacuate the facility as soon as possible. Gina and Colette escort Rosenberg through the Hazard Course to a satellite communications center on the surface, where he is able to transmit a distress signal. Dr. Rosenberg decides to wait there for the military, and this is the last time he is seen in Decay as Gina and Colette return below to assist Dr. Keller. However, his voice is heard once more in the game later on.
== Structure == GnIH is a neurohormone classified as an RFamide (RFa) or RFamide-related peptide (RFRP), coded by the NPVF gene in mammals. The complete amino acid sequence varies by species, but all RFa and RFRP peptides contain an arginine-phenylalanine-amine sequence at the C-terminal. This is seen in both Coturnix Japonica GnIH RFa (Ser-Ile-Lys-Pro-Ser-Ala-Tyr-Leu-Pro-Leu-Arg-Phe-NH2), and the human homolog, RFRP-3 (Val-Pro-Asp-Leu-Pro-Glu-Arg-Phe-NH2).
Odi: 354,782 Moretele: 235,540 Tlhaping-Tlharo: 101,425 Ditsobotla: 135,045 Molopo: 128,383 Mankwe: 89,841 Bafokeng: 88,399 Taung: 134,277 Thaba 'Nchu: 49,053 Lehurutshe: 62,901 Madikwe: 52,268 Ganyesa: 47,036 Major cities and towns in Bophuthatswana included:
Electron transfers Electron transfer (ET) between metal ions can occur via two distinct mechanisms, inner and outer sphere electron transfers. In an inner sphere reaction, a bridging ligand serves as a conduit for ET. (Degenerate) ligand exchange One important indicator of reactivity is the rate of degenerate exchange of ligands. For example, the rate of interchange of coordinate water in [M(H2O)6]n+ complexes varies over 20 orders of magnitude. Complexes where the ligands are released and rebound rapidly are classified as labile. Such labile complexes can be quite stable thermodynamically. Typical labile metal complexes either have low-charge (Na+), electrons in d-orbitals that are antibonding with respect to the ligands (Zn2+), or lack covalency (Ln3+, where Ln is any lanthanide). The lability of a metal complex also depends on the high-spin vs. low-spin configurations when such is possible. Thus, high-spin Fe(II) and Co(III) form labile complexes, whereas low-spin analogues are inert. Cr(III) can exist only in the low-spin state (quartet), which is inert because of its high formal oxidation state, absence of electrons in orbitals that are M–L antibonding, plus some "ligand field stabilization" associated with the d3 configuration. Associative processes Complexes that have unfilled or half-filled orbitals are often capable of reacting with substrates. Most substrates have a singlet ground-state; that is, they have lone electron pairs (e.g., water, amines, ethers), so these substrates need an empty orbital to be able to react with a metal centre.
Sources: en.wikipedia.org
The district's borders, which correspond to the former city's borders, are: Victoria Park Avenue (facing the rest of Toronto) to the west, the Rouge River, the Little Rouge Creek and the Scarborough-Pickering Townline (facing Pickering) to the east, Steeles Avenue (facing Markham) to the north, and Lake Ontario to the south. Topographically, the district is dominated by two watersheds, Highland Creek and the Rouge River. Highland Creek lies almost entirely within Scarborough and occupies approximately 70% of its total area. It occupies the western half of Scarborough, while the Rouge River flows through the eastern portion. Both of these rivers flow into Lake Ontario. Due to the location of the Lakeshore CN railway right-of-way, both river deltas are constricted to narrow channels where they flow into the lake. Highland Creek is the most urbanized watershed in Toronto with about 85% of its land use devoted to urban uses. Some sections of the river run through parks and remain in a fairly natural state, while other parts run through industrial or residential districts where the flow is often diverted or channelled. Sections of the creek are marked by deep ravines and valleys, which contain little or no urban development. The deep valley the creek cuts in its bottom sections remains primarily parkland, with little or no development taking place within the valley. Conversely, the Rouge River valley has parts which are still in a natural, wooded state.
October 27, 1946: The Preamble to the Constitution of October 27, 1946, establishes the Fourth Republic in France; it includes in paragraph 3 the statement: "The law guarantees women equal rights with men in all areas."
==== Probing pocket depth (PPD) ==== Pocket depth is the distance from the gingival margin to the base of the pocket. The position of the gingival margin can change due to swelling or recession, and vary with inflammation if force of probing, therefore, probing depth measurement alone is not recommended for assessment of changes in periodontal support over time.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.